Compounded GLP-1s: what TikTok gets right and wrong

What did @brian.faitala actually say?

At the 48-hour mark after his first compounded GLP-1 dose, Brian reported an energy boost he attributes to B12 or NAD, milder sulfur burps than he experienced on branded semaglutide, and no GI issues like diarrhea or constipation. He also said he "thinks" both versions contain "the same ingredient, same dose" but admitted he doesn't fully understand how they compare.

To his credit, he hedged almost every claim. He said "I don't know if it's the B12" and "I don't know if it's a state of mind thing." That kind of self-awareness is rare in GLP-1 content. But 48 hours is not enough time to draw meaningful conclusions about efficacy, tolerability, or additive ingredient effects, and his framing that he'll "never go back to branded" after two days is getting ahead of the data by a wide margin.

Does the science back this up?

The B12 energy claim is plausible only in a narrow context. If someone is B12-deficient, supplementation can meaningfully improve fatigue. In people with normal B12 levels, the evidence for an energy boost is weak at best.

A 2019 Cochrane review by Normand et al. found no consistent benefit of B12 supplementation on fatigue in non-deficient adults. GLP-1 medications can deplete B12 over time, particularly in patients who were already borderline low, so including it in a formulation isn't irrational. But Brian's reported boost at 48 hours is almost certainly a placebo response or novelty effect, not a pharmacological one. B12 doesn't produce noticeable energy changes within two days unless the person was genuinely deficient beforehand.

As for NAD, the data on oral or injectable NAD precursors for energy is preliminary. Studies like Yoshino et al. (2021, Science) showed metabolic improvements in specific populations, but these were controlled trials, not anecdotes at 48 hours post-injection.

What did they get wrong (or right)?

Brian got the uncertainty right. His repeated "I don't know" framing is honest and appropriate for a 48-hour personal report.

Where he went wrong: saying it's "supposed to be the same ingredient, same dose" conflates compounded and branded GLP-1 products in a way that regulators and researchers explicitly caution against. The FDA has stated that compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic. Compounded products are not required to demonstrate bioequivalence, and the base molecule used by many compounders (semaglutide sodium or acetate salt forms) may differ from the branded formulation. Claiming equivalency, even casually, misleads viewers who may be making treatment decisions.

His observation that sulfur burps arrived faster with compounded is interesting but not interpretable. Side effect timing varies with formulation, absorption rate, injection technique, what he ate, and a dozen other variables. One data point from one person proves nothing.

What should you actually know?

Compounded GLP-1 medications exist in a genuinely complicated regulatory space. The FDA placed both semaglutide and tirzepatide on its shortage list, which temporarily allowed compounding pharmacies to produce copies. That window is closing. In early 2025, the FDA declared the shortage resolved and began enforcement actions against compounders.

The addition of B12 and NAD to compounded formulations is a common upsell. There is no peer-reviewed evidence that these combinations improve GLP-1 outcomes, reduce side effects, or perform better than the active ingredient alone. They may be harmless, but "harmless upsell" is not the same as "effective add-on."

If you are considering compounded GLP-1 therapy, the legitimate questions to ask are: Is this pharmacy 503A or 503B accredited? Has the product been third-party tested for potency and sterility? Is your provider monitoring you clinically, not just filling a form? Brian's video is a personal diary entry, not medical guidance, and he says so himself. That's the right framing.